Literature DB >> 9179379

Inhibition of arginase in rat and rabbit alveolar macrophages by N omega-hydroxy-D,L-indospicine, effects on L-arginine utilization by nitric oxide synthase.

C Hey1, J L Boucher, S Vadon-Le Goff, G Ketterer, I Wessler, K Racké.   

Abstract

1. Alveolar macrophages (AM phi) exhibit arginase activity and may, in addition, express an inducible form of nitric oxide (NO) synthase (iNOS). Both pathways may compete for the substrate. L-arginine. The present study tested whether two recently described potent inhibitors of liver arginase (N omega-hydroxy-D,L-indospicine and 4-hydroxyamidino-D,L-phenylalanine) might also inhibit arginase in AM phi and whether inhibition of arginase might affect L-arginine utilization by iNOS. 2. AM phi obtained by broncho-alveolar lavage of rat and rabbit isolated lungs were disseminated (2.5 or 3 x 10(6) cells per well) and allowed to adhere for 2 h. Thereafter, they were either used to study [3H]-L-arginine uptake (37 kBq, 0.1 microM, 2 min) or cultured for 20 h in the absence or presence of bacterial lipopolysaccharide (LPS). Cultured AM phi were incubated for 1 h with [3H]-L-arginine (37 kBq, 0.1 microM) and the accumulation of [3H]-L-citrulline (NOS activity) and [3H]-L-ornithine (arginase activity) was determined. 3. During 1 h incubation of rabbit AM phi with [3H]-L-arginine, no [3H]-L-citrulline, but significant amounts of [3H]-L-ornithine (150 d.p.m x 1000) were formed. N omega-hydroxy-D,L-indospicine and 4-hydroxyamidino-D,L-phenylalanine, present during incubation, concentration-dependently reduced [3H]-L-ornithine formation (IC50: 2 and 45 microM, respectively). 4. N omega-hydroxy-D,L-indospicine (up to 100 microM) had no effect on [3H]-L-arginine uptake into rabbit AM phi, whereas 4-hydroxyamidino-D,L-phenylalanine caused a concentration-dependent inhibition (IC50: 300 microM). 5. Rat AM phi, cultured in the absence of LPS, formed significant amounts of [3H]-L-citrulline and [3H]-L-ornithine (133 and 212 d.p.m x 1000, respectively) when incubated for 1 h with [3H]-L-arginine. When AM phi had been cultured in the presence of 0.1 or 1 microgram ml-1 LPS, the formation of [3H]-L-citrulline was enhanced by 37 +/- 8.3 and 99 +/- 12% and that of [3H]-L-ornithine reduced by 21 +/- 8.7 and 70 +/- 2.5%, respectively. 6. In rat AM phi, cultured in the absence or presence of LPS, N omega-hydroxy-D,L-indospicine (10 and 30 microM) greatly reduced formation of [3H]-L-ornithine (by 80-95%) and this was accompanied by increased formation of [3H]-L-citrulline. However, only 20-30% of the [3H]-L-arginine not metabolized to [3H]-L-ornithine after inhibition of arginase was metabolized to [3H]-L-citrulline, when the AM phi had been cultured in the absence of LPS (i.e. low level of iNOS). On the other hand, when the AM phi had been cultured in the presence of LPS (i.e. high level of iNOS), all the [3H]-L-arginine not metabolized by the inhibited arginase was metabolized to [3H]-L-citrulline. 7. In conclusion, N omega-hydroxy-D,L-indospicine is a potent and specific inhibitor of arginase in AM phi. In cells in which, in addition to arginase, iNOS is expressed, inhibition of arginase can cause a shift of L-arginine metabolism to the NOS pathway. However, the extent of this shift appears to depend in a complex manner on the level of iNOS.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9179379      PMCID: PMC1564700          DOI: 10.1038/sj.bjp.0701143

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  25 in total

Review 1.  Arginase: a critical regulator of nitric oxide synthesis and vascular function.

Authors:  William Durante; Fruzsina K Johnson; Robert A Johnson
Journal:  Clin Exp Pharmacol Physiol       Date:  2007-09       Impact factor: 2.557

2.  Inhibition of nitric oxide synthase abrogates lipopolysaccharides-induced up-regulation of L-arginine uptake in rat alveolar macrophages.

Authors:  R Hammermann; C Stichnote; E I Closs; H Nawrath; K Racké
Journal:  Br J Pharmacol       Date:  2001-06       Impact factor: 8.739

3.  Glucocorticoids inhibit lipopolysaccharide-induced up-regulation of arginase in rat alveolar macrophages.

Authors:  S Klasen; R Hammermann; M Fuhrmann; D Lindemann; K F Beck; J Pfeilschifter; K Racké
Journal:  Br J Pharmacol       Date:  2001-03       Impact factor: 8.739

4.  Modulation of cholinergic airway reactivity and nitric oxide production by endogenous arginase activity.

Authors:  H Meurs; M A Hamer; S Pethe; S Vadon-Le Goff; J L Boucher; J Zaagsma
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

5.  Role of L-arginine in the deficiency of nitric oxide and airway hyperreactivity after the allergen-induced early asthmatic reaction in guinea-pigs.

Authors:  J Boer; M Duyvendak; F E Schuurman; F M Pouw; J Zaagsma; H Meurs
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

6.  Arginase I expression and activity in human mononuclear cells after injury.

Authors:  J B Ochoa; A C Bernard; W E O'Brien; M M Griffen; M E Maley; A K Rockich; B J Tsuei; B R Boulanger; P A Kearney; S M Morris
Journal:  Ann Surg       Date:  2001-03       Impact factor: 12.969

7.  Activation of L-arginine transport by protein kinase C in rabbit, rat and mouse alveolar macrophages.

Authors:  K Racké; C Hey; J Mössner; R Hammermann; C Stichnote; I Wessler
Journal:  J Physiol       Date:  1998-09-15       Impact factor: 5.182

Review 8.  Arginase: a key enzyme in the pathophysiology of allergic asthma opening novel therapeutic perspectives.

Authors:  Harm Maarsingh; Johan Zaagsma; Herman Meurs
Journal:  Br J Pharmacol       Date:  2009-08-24       Impact factor: 8.739

Review 9.  Arginine metabolism: nitric oxide and beyond.

Authors:  G Wu; S M Morris
Journal:  Biochem J       Date:  1998-11-15       Impact factor: 3.857

10.  Hydroxyurea generates nitric oxide in human erythroid cells: mechanisms for gamma-globin gene activation.

Authors:  Tzu-Fang Lou; Manisha Singh; Ashley Mackie; Wei Li; Betty S Pace
Journal:  Exp Biol Med (Maywood)       Date:  2009-08-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.